Time reports that some experts have raised concerns about 23andMe's new direct-to-consumer pharmacogenetic tests.
The companies have launched a center that offers consulting and management specifically for genomically targeted or precision medicine trials.
The companies are creating a new center that will offer support services to biopharmaceutical companies, CROs, and others in designing genetically informed clinical trials.
The company will now offer free genetic testing to patients at risk for acute hepatic porphyrias, a class of diseases for which it is developing a treatment.
The companies are working together to help insurers reduce wasteful spending and spur use of medically necessary tests.
Cigna worked with InformedDNA to come up with scenarios under which it would cover whole-exome sequencing, although it still considers whole-genome analysis investigational.
A University of California, Los Angeles-led team has found turning off the CCR5 gene could improve recovery after a stroke, according to Scientific American.
South Dakota lawmakers are to weigh a bill aimed at teaching the strengths and weaknesses of scientific concepts, the Associated Press and KEVN-Black Hills Fox report.
In Science this week: the synthetic genetic system hachimoji, and more.
Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.